CGEM

Cullinan Therapeutics Inc. (CGEM) | Rumor.io

Cullinan Therapeutics

CGEM

Attention (50-day avg)0%

Attention rank (50-day avg)#1,445

Bullish sentiment (50-day avg)89%

Price to earnings ratio9.03

Market capitalization962.1M

Earnings per share-3.11

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-219.9M

Social

What share of all stock conversation is about CGEM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% +0

Sep 14

Cullinan Therapeutics' zipalertinib plus chemotherapy demonstrated a 6-month median progression-free survival benefit in a Phase 3 trial in first-line EGFR exon 20 insertion mutation non-small cell lung cancer.
The trial showed a median progression-free survival of 14.5 months versus 8.5 months in a lung cancer study, with a safety caveat but a favorable efficacy profile.
The results are considered a new standard of care (SOC) and make zipalertinib a "non-brainer" to use in these patients due to its CNS metastatic activity.

Generated by AI

Sentiment

Of the messages about CGEM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	11.11%	84.68% -15.32	89.49% +10.54
Bearish	—	88.89%	15.32% +15.32	10.51% -10.54

Nov 24

$CGEM has strong chart momentum and a high-probability breakout setup, with momentum, volatility, and volume all confirming accumulation.
Cullinan Therapeutics ($CGEM) has a strong cash position of $475 million and a potential milestone payment from Taiho due to the Zipa submission.
$CGEM has a buy rating from BTIG with a target price of $38, and is showing signs of a short-squeeze potential with a short ratio of 6.68 and a short float of 16.51%.

Generated by AI

Topics

Of the messages about CGEM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	20%	36.69%	66.67%
Technical Analysis	100%	70%	31.82%	20.39%
Analysts	0%	10%	1.95%	2.71%
Macro	0%	0%	29.55%	10.23%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%

Jan 29

Cullinan Therapeutics' Phase 2b trial for Zipalertinib in NSCLC patients with EGFR exon 20 insertions met its primary endpoint.
The company plans to submit a regulatory approval application for Zipalertinib in the second half of 2025.
H.C. Wainwright raised its price target on Cullinan Therapeutics to $33 from $28 and maintains a Buy rating following the announcement.

Generated by AI

Community

Of the messages about CGEM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	64.29%	65.51%	9.7%
Newcomers	100%	35.71%	34.49%	90.3%

Regulars· Apr 16

Cullinan Therapeutics, Inc. (CGEM) is expanding its focus towards autoimmune diseases, potentially leading to new treatment options and revenue streams.
The company's shares jumped 20.5% after announcing the strategic expansion, indicating market optimism about the new direction.
CGEM's move into autoimmune diseases may position the company to capitalize on the growing demand for treatments in this area, as seen in the success of other companies in the space.

Newcomers· Nov 24

The newcomer is excited about the potential breakout of Cullinan Therapeutics, Inc. ($CGEM), with strong momentum, elevated volatility, and heavy option flow near key strikes.
The stock has shown a significant increase, with a 37% jump, and the newcomer is looking for further upside, with a target price of $11.50.
The newcomer believes that the chart looks very good, and there's a possibility of a pullback, but overall, the stock has a clear price path to $15, with rising call activity and positive gamma ramp supporting further upside.

Generated by AI

News

Cullinan Therapeutics: Compelling Pullback For CLN-978’s Potential In Autoimmune Diseases

Cullinan Therapeutics' stock pullback may be a strong entry ahead of December 2026 autoimmune updates. Read more on CGEM here.

1d agoSeeking Alpha

Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049

Cullinan Therapeutics (NASDAQ:CGEM) outlined upcoming clinical milestones across its immunology and oncology pipeline, including a planned December update for its CD19-directed T-cell engager CLN-978 and data presentations for other programs in November and the fourth quarter. President and CEO Nad

2d agoYahoo Finance

Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026

Cullinan Therapeutics (NasdaqGS:CGEM) plans to report clinical data updates from three T cell engager programs in Q4 2026. The update will include new results for autoimmune and oncology candidates Velinotamig, CLN-978, and CLN-049. Cullinan also anticipates starting a Phase 2 study of CLN-049 after discussions with the US Food and Drug Administration. The planned Q4 2026 readouts and CLN-049 Phase 2 launch sit alongside a broader picture our research has uncovered. Take a look at 3 warning...

3d agoYahoo Finance

Cullinan Therapeutics at stifel 2026 forum: autoimmune pipeline advances

5d agoInvesting.com

Cullinan delays early-stage data for arthritis drug (CGEX)

5d agoSeeking Alpha

Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs

5d agoYahoo Finance

Also Discussed

Investors talking about CGEM also mention

#	Name	Attention
1	Arcus Biosciences, Inc.RCUS	0%new
2	Kulicke & Soffa Industries, Inc.KLIC	0%0
3	Kymera Therapeutics Inc.KYMR	0%0
4	Cohu, Inc.COHU	0.02%+0
5	Relay Therapeutics Inc.RLAY	0%new
6	Extreme Networks Inc.EXTR	0%new
7	Xometry Inc.XMTR	0%new
8	Ultra Clean Holdings, Inc.UCTT	0%0
9	Nurix Therapeutics, Inc.NRIX	0%new
10	Ichor Holdings, Ltd.ICHR	0%0

Cullinan Therapeutics Inc.

Healthcare
Biotechnology

Cullinan Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases and cancer. The company builds its pipeline around targeted and immune-based approaches, including T cell engagers, bispecific antibodies, monoclonal antibodies, and small-molecule candidates. Its current programs address a range of serious conditions across oncology and immunology, such as non-small cell lung cancer, acute myeloid leukemia, multiple myeloma, systemic lupus erythematosus, and rheumatoid arthritis. Cullinan Therapeutics works to advance differentiated drug candidates through early- and mid-stage clinical development, with a business model centered on discovering high-impact molecules and moving them toward proof of concept. Based in Cambridge, Massachusetts, Cullinan Therapeutics plays a role in the biotechnology market as a developer of precision therapies for diseases with significant unmet medical need.

Website

Location

One Main Street

Cambridge, MA, 02142

United States

Social

What share of all stock conversation is about CGEM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% +0

Sep 14

Cullinan Therapeutics' zipalertinib plus chemotherapy demonstrated a 6-month median progression-free survival benefit in a Phase 3 trial in first-line EGFR exon 20 insertion mutation non-small cell lung cancer.
The trial showed a median progression-free survival of 14.5 months versus 8.5 months in a lung cancer study, with a safety caveat but a favorable efficacy profile.
The results are considered a new standard of care (SOC) and make zipalertinib a "non-brainer" to use in these patients due to its CNS metastatic activity.

Generated by AI

Sentiment

Of the messages about CGEM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	11.11%	84.68% -15.32	89.49% +10.54
Bearish	—	88.89%	15.32% +15.32	10.51% -10.54

Nov 24

$CGEM has strong chart momentum and a high-probability breakout setup, with momentum, volatility, and volume all confirming accumulation.
Cullinan Therapeutics ($CGEM) has a strong cash position of $475 million and a potential milestone payment from Taiho due to the Zipa submission.
$CGEM has a buy rating from BTIG with a target price of $38, and is showing signs of a short-squeeze potential with a short ratio of 6.68 and a short float of 16.51%.

Generated by AI

Topics

Of the messages about CGEM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	20%	36.69%	66.67%
Technical Analysis	100%	70%	31.82%	20.39%
Analysts	0%	10%	1.95%	2.71%
Macro	0%	0%	29.55%	10.23%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%

Jan 29

Cullinan Therapeutics' Phase 2b trial for Zipalertinib in NSCLC patients with EGFR exon 20 insertions met its primary endpoint.
The company plans to submit a regulatory approval application for Zipalertinib in the second half of 2025.
H.C. Wainwright raised its price target on Cullinan Therapeutics to $33 from $28 and maintains a Buy rating following the announcement.

Generated by AI

Community

Of the messages about CGEM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	64.29%	65.51%	9.7%
Newcomers	100%	35.71%	34.49%	90.3%

Regulars· Apr 16

Cullinan Therapeutics, Inc. (CGEM) is expanding its focus towards autoimmune diseases, potentially leading to new treatment options and revenue streams.
The company's shares jumped 20.5% after announcing the strategic expansion, indicating market optimism about the new direction.
CGEM's move into autoimmune diseases may position the company to capitalize on the growing demand for treatments in this area, as seen in the success of other companies in the space.

Newcomers· Nov 24

The newcomer is excited about the potential breakout of Cullinan Therapeutics, Inc. ($CGEM), with strong momentum, elevated volatility, and heavy option flow near key strikes.
The stock has shown a significant increase, with a 37% jump, and the newcomer is looking for further upside, with a target price of $11.50.
The newcomer believes that the chart looks very good, and there's a possibility of a pullback, but overall, the stock has a clear price path to $15, with rising call activity and positive gamma ramp supporting further upside.

Generated by AI

Cullinan Therapeutics

Social

Sep 14

Nov 24

Jan 29

Regulars· Apr 16

Newcomers· Nov 24

Cullinan Therapeutics: Compelling Pullback For CLN-978’s Potential In Autoimmune Diseases

Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049

Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026

Cullinan Therapeutics at stifel 2026 forum: autoimmune pipeline advances

Cullinan delays early-stage data for arthritis drug (CGEX)

Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs

Also Discussed

Cullinan Therapeutics Inc.

Company Information

Location

Cullinan Therapeutics: Compelling Pullback For CLN-978’s Potential In Autoimmune Diseases

Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049

Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026

Cullinan Therapeutics at stifel 2026 forum: autoimmune pipeline advances

Cullinan delays early-stage data for arthritis drug (CGEX)

Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs

Also Discussed

Social

Sep 14

Nov 24

Jan 29

Regulars· Apr 16

Newcomers· Nov 24